Terms: = Leukemia AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169
480 results:
1. Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients.
Borsi E; Vigliotta I; Poletti A; Mazzocchetti G; Solli V; Zazzeroni L; Martello M; Armuzzi S; Taurisano B; Kanapari A; Pistis I; Zamagni E; Pantani L; Rocchi S; Mancuso K; Tacchetti P; Rizzello I; Rizzi S; Dan E; Sinigaglia B; Cavo M; Terragna C
Cells; 2024 Apr; 13(8):. PubMed ID: 38667272
[TBL] [Abstract] [Full Text] [Related]
2. A novel t(X;21)(p11.4;q22.12) translocation adds to the role of BCOR and RUNX1 in myelodysplastic syndromes and acute myeloid leukemias.
Mavridou E; Lema Fernandez AG; Nardelli C; Pierini V; Quintini M; Arniani S; Di Giacomo D; Crescenzi B; Matteucci C; Sambani C; Mecucci C
Genes Chromosomes Cancer; 2024 Apr; 63(4):e23235. PubMed ID: 38656651
[TBL] [Abstract] [Full Text] [Related]
3. Unlocking adult T-cell leukemia/lymphoma's epigenetic secrets: delving into the mechanism and impact of EZH1/2 inhibition.
Tavakoli Shirazi P; Bywater MJ
Immunol Cell Biol; 2024; 102(5):298-301. PubMed ID: 38606590
[TBL] [Abstract] [Full Text] [Related]
4. Genome-wide DNA methylation-analysis of blastic plasmacytoid dendritic cell neoplasm identifies distinct molecular features.
Künstner A; Schwarting J; Witte HM; Xing P; Bernard V; Stölting S; Lohneis P; Janke F; Salehi M; Chen X; Kusch K; Sültmann H; Chteinberg E; Fischer A; Siebert R; von Bubnoff N; Merz H; Busch H; Feller AC; Gebauer N
Leukemia; 2024 May; 38(5):1086-1098. PubMed ID: 38600314
[TBL] [Abstract] [Full Text] [Related]
5. Construction and experimental validation of a novel ferroptosis-related gene signature for myelodysplastic syndromes.
Zhu Y; He J; Wei R; Liu J
Immun Inflamm Dis; 2024 Apr; 12(4):e1221. PubMed ID: 38578040
[TBL] [Abstract] [Full Text] [Related]
6. Genomic and global gene expression profiling in pediatric and young adult acute leukemia with PICALM::MLLT10 Fusion.
Ma J; Liu YC; Voss RK; Ma J; Palagani A; Caldwell E; Rosikiewicz W; Cardenas M; Foy S; Umeda M; Wilkinson MR; Inaba H; Klco JM; Rubnitz JE; Wang L
Leukemia; 2024 May; 38(5):981-990. PubMed ID: 38429501
[TBL] [Abstract] [Full Text] [Related]
7. Mechanisms of action and resistance in histone methylation-targeted therapy.
Yamagishi M; Kuze Y; Kobayashi S; Nakashima M; Morishima S; Kawamata T; Makiyama J; Suzuki K; Seki M; Abe K; Imamura K; Watanabe E; Tsuchiya K; Yasumatsu I; Takayama G; Hizukuri Y; Ito K; Taira Y; Nannya Y; Tojo A; Watanabe T; Tsutsumi S; Suzuki Y; Uchimaru K
Nature; 2024 Mar; 627(8002):221-228. PubMed ID: 38383791
[TBL] [Abstract] [Full Text] [Related]
8. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
Shimony S; Bewersdorf JP; Shallis RM; Liu Y; Schaefer EJ; Zeidan AM; Goldberg AD; Stein EM; Marcucci G; Lindsley RC; Chen EC; Ramos Perez J; Stein A; DeAngelo DJ; Neuberg DS; Stone RM; Ball B; Stahl M
Leukemia; 2024 Apr; 38(4):762-768. PubMed ID: 38378841
[TBL] [Abstract] [Full Text] [Related]
9. Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt-related transcription factor 1 mutation: A single-center retrospective analysis.
Wang LY; Li Y; Jiang Q; Jiang H; Wang Y; Xu LP; Zhang XH; Liu KY; Tang FF
Hematol Oncol; 2024 Mar; 42(2):e3256. PubMed ID: 38367260
[TBL] [Abstract] [Full Text] [Related]
10. Discovery of a novel, highly potent ezh2 PROTAC degrader for targeting non-canonical oncogenic functions of ezh2.
Velez J; Dale B; Park KS; Kaniskan HÜ; Yu X; Jin J
Eur J Med Chem; 2024 Mar; 267():116154. PubMed ID: 38295690
[TBL] [Abstract] [Full Text] [Related]
11. FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia.
Sung PJ; Selvam M; Riedel SS; Xie HM; Bryant K; Manning B; Wertheim GB; Kulej K; Pham L; Bowman RL; Peresie J; Nemeth MJ; Levine RL; Garcia BA; Meyer SE; Sidoli S; Bernt KM; Carroll M
Leukemia; 2024 Feb; 38(2):291-301. PubMed ID: 38182819
[TBL] [Abstract] [Full Text] [Related]
12.
Choi YJ; Min YK; Lee ST; Choi JR; Shin S
Ann Lab Med; 2024 Jul; 44(4):335-342. PubMed ID: 38145892
[TBL] [Abstract] [Full Text] [Related]
13. JAK2 R683S Mutation Resulting in Dual Diagnoses of Chronic Eosinophilic leukemia and Myelodysplastic/Myeloproliferative Overlap Syndrome.
Krah NM; Miotke L; Li P; Patel JL; Bowen AR; Pomicter AD; Patel AB
J Natl Compr Canc Netw; 2023 Dec; 21(12):1218-1223. PubMed ID: 38081125
[TBL] [Abstract] [Full Text] [Related]
14. Epigenetic vulnerabilities of leukemia harboring inactivating ezh2 mutations.
Alqazzaz MA; Luciani GM; Vu V; Machado RAC; Szewczyk MM; Adamson EC; Cheon S; Li F; Arrowsmith CH; Minden MD; Barsyte-Lovejoy D
Exp Hematol; 2024 Feb; 130():104135. PubMed ID: 38072134
[TBL] [Abstract] [Full Text] [Related]
15. ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.
Arribas AJ; Napoli S; Cascione L; Barnabei L; Sartori G; Cannas E; Gaudio E; Tarantelli C; Mensah AA; Spriano F; Zucchetto A; Rossi FM; Rinaldi A; Castro de Moura M; Jovic S; Bordone Pittau R; Stathis A; Stussi G; Gattei V; Brown JR; Esteller M; Zucca E; Rossi D; Bertoni F
Mol Cancer Ther; 2024 Mar; 23(3):368-380. PubMed ID: 38052765
[TBL] [Abstract] [Full Text] [Related]
16. [Clonal hematopoiesis and its evolution of myeloproliferative neoplasms].
Zhang L; Dong H
Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3608-3614. PubMed ID: 38018059
[TBL] [Abstract] [Full Text] [Related]
17. Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.
Jain N; Croner LJ; Allan JN; Siddiqi T; Tedeschi A; Badoux XC; Eckert K; Cheung LWK; Mukherjee A; Dean JP; Szafer-Glusman E; Seymour JF
Clin Cancer Res; 2024 Feb; 30(3):498-505. PubMed ID: 37955424
[TBL] [Abstract] [Full Text] [Related]
18. Synchronous T-lymphoblastic lymphoma and neuroblastoma in a 3-yr-old with novel germline
Tibout P; Livingston J; Kanwar N; Yuki KE; Shlien A; Ngan B; Irwin MS; Morgenstern DA; Hitzler J; Villani A; Cohen-Gogo S
Cold Spring Harb Mol Case Stud; 2023 Dec; 9(4):. PubMed ID: 37932047
[TBL] [Abstract] [Full Text] [Related]
19. Comprehensive genomic profiling reveals molecular subsets of
Johnson SM; Haberberger J; Galeotti J; Ramkissoon L; Coombs CC; Richardson DR; Foster MC; Duncan D; Montgomery ND; Ferguson NL; Zeidner JF
Leuk Lymphoma; 2024 Feb; 65(2):209-218. PubMed ID: 37921062
[TBL] [Abstract] [Full Text] [Related]
20. MEK/ERK and PI3K/AKT pathway inhibitors affect the transformation of myelodysplastic syndrome into acute myeloid leukemia via H3K27me3 methylases and de‑methylases.
Zheng Z; Chen X; Zhang Y; Ren F; Ma Y
Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37921060
[TBL] [Abstract] [Full Text] [Related]
[Next]
